IL149488A0 - Pharmaceutical compositions containing aplidine - Google Patents

Pharmaceutical compositions containing aplidine

Info

Publication number
IL149488A0
IL149488A0 IL14948800A IL14948800A IL149488A0 IL 149488 A0 IL149488 A0 IL 149488A0 IL 14948800 A IL14948800 A IL 14948800A IL 14948800 A IL14948800 A IL 14948800A IL 149488 A0 IL149488 A0 IL 149488A0
Authority
IL
Israel
Prior art keywords
aplidine
pharmaceutical compositions
compositions containing
tumor
containing aplidine
Prior art date
Application number
IL14948800A
Other languages
English (en)
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927006.8A external-priority patent/GB9927006D0/en
Priority claimed from GB0005701A external-priority patent/GB0005701D0/en
Priority claimed from GB0007639A external-priority patent/GB0007639D0/en
Priority claimed from GB0015496A external-priority patent/GB0015496D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of IL149488A0 publication Critical patent/IL149488A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14948800A 1999-11-15 2000-11-15 Pharmaceutical compositions containing aplidine IL149488A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9927006.8A GB9927006D0 (en) 1999-11-15 1999-11-15 Aplidine treatment of cancers
GB0005701A GB0005701D0 (en) 2000-03-09 2000-03-09 Antitumor utility of aplidine
GB0007639A GB0007639D0 (en) 2000-03-29 2000-03-29 Antitumour and anti-angiogenic compound
GB0015496A GB0015496D0 (en) 2000-06-23 2000-06-23 Antitumour and anti-angiogenic compound
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers
PCT/GB2000/004349 WO2001035974A2 (en) 1999-11-15 2000-11-15 Aplidine treatment of cancers

Publications (1)

Publication Number Publication Date
IL149488A0 true IL149488A0 (en) 2002-11-10

Family

ID=27515929

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14948800A IL149488A0 (en) 1999-11-15 2000-11-15 Pharmaceutical compositions containing aplidine

Country Status (27)

Country Link
US (1) US20090298752A1 (de)
EP (1) EP1229922B1 (de)
JP (1) JP2003514025A (de)
KR (1) KR100518986B1 (de)
CN (1) CN1423564A (de)
AT (1) ATE363910T1 (de)
AU (1) AU780417B2 (de)
BG (1) BG65381B1 (de)
BR (1) BR0015811A (de)
CA (1) CA2391502A1 (de)
CY (1) CY1106825T1 (de)
CZ (1) CZ302498B6 (de)
DE (1) DE60035120T2 (de)
DK (1) DK1229922T3 (de)
ES (1) ES2288486T3 (de)
HK (1) HK1045648B (de)
HU (1) HUP0203906A2 (de)
IL (1) IL149488A0 (de)
MX (1) MXPA02004862A (de)
NO (1) NO330719B1 (de)
NZ (1) NZ518847A (de)
PL (1) PL200922B1 (de)
PT (1) PT1229922E (de)
RU (1) RU2261104C2 (de)
SI (1) SI1229922T1 (de)
SK (1) SK287762B6 (de)
WO (1) WO2001035974A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
BR0114604A (pt) 2000-10-12 2003-10-14 Pharma Mar Sa Tratamento de c‰nceres
EP1435991B1 (de) * 2001-10-19 2008-10-15 Pharma Mar, S.A. Verwendung von aplidine in der behandlung von pankreaskrebs
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
KR20060002778A (ko) * 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료
JP4584245B2 (ja) 2003-03-12 2010-11-17 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 多発性骨髄腫治療用のアプリジン
HUE028055T2 (en) * 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
EP2117539B1 (de) * 2006-11-03 2010-09-01 Nerviano Medical Sciences S.r.l. Verfahren zur verabreichung einer antitumoralen verbindung
RU2360712C1 (ru) * 2007-10-02 2009-07-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ лечения местно-распространенного неоперабельного рака прямой кишки
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
CN101965191A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗癌治疗
CN103463020B (zh) * 2013-09-23 2015-11-25 李淑兰 Lycojaponicumin A在制备治疗肾癌药物中的应用
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
DE3161556D1 (en) * 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
ATE74761T1 (de) * 1985-09-20 1992-05-15 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5580871A (en) * 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
DE69431071T2 (de) * 1993-12-29 2003-03-20 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
EP0914116B1 (de) * 1996-05-22 2000-10-11 Protarga Inc. Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
WO1998050048A1 (en) * 1997-05-07 1998-11-12 Pharma Mar, S.A. Aplidine as an l-type calcium channel enhancer
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
ES2272462T3 (es) * 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
AU1305302A (en) * 2000-10-05 2002-04-15 Immunex Corp Nectin polypeptides, polynucleotides, methods of making and use thereof
BR0114604A (pt) * 2000-10-12 2003-10-14 Pharma Mar Sa Tratamento de c‰nceres
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US6610399B1 (en) * 2000-11-17 2003-08-26 Structural Technologies, Llc Multi-layer, thermal protection and corrosion protection coating system for metallic tendons, especially for external post-tensioning systems
EP1435991B1 (de) * 2001-10-19 2008-10-15 Pharma Mar, S.A. Verwendung von aplidine in der behandlung von pankreaskrebs
KR20060002778A (ko) * 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료
JP4584245B2 (ja) * 2003-03-12 2010-11-17 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 多発性骨髄腫治療用のアプリジン
AU2004224418A1 (en) * 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
HUE028055T2 (en) * 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments

Also Published As

Publication number Publication date
CY1106825T1 (el) 2012-05-23
EP1229922A2 (de) 2002-08-14
NO20022293L (no) 2002-07-05
SI1229922T1 (sl) 2008-04-30
CN1423564A (zh) 2003-06-11
AU780417B2 (en) 2005-03-17
HUP0203906A2 (en) 2003-03-28
NO20022293D0 (no) 2002-05-14
MXPA02004862A (es) 2003-01-28
ES2288486T3 (es) 2008-01-16
HK1045648A1 (en) 2002-12-06
KR20020064313A (ko) 2002-08-07
AU1402301A (en) 2001-05-30
WO2001035974A2 (en) 2001-05-25
JP2003514025A (ja) 2003-04-15
EP1229922B1 (de) 2007-06-06
BG106714A (en) 2003-02-28
DK1229922T3 (da) 2007-10-08
SK6592002A3 (en) 2003-08-05
SK287762B6 (sk) 2011-09-05
WO2001035974A3 (en) 2001-11-01
PL200922B1 (pl) 2009-02-27
DE60035120T2 (de) 2008-01-31
NZ518847A (en) 2004-02-27
BR0015811A (pt) 2002-08-06
PT1229922E (pt) 2007-09-12
BG65381B1 (bg) 2008-05-30
CZ302498B6 (cs) 2011-06-15
RU2002115864A (ru) 2004-01-20
CA2391502A1 (en) 2001-05-25
ATE363910T1 (de) 2007-06-15
KR100518986B1 (ko) 2005-10-06
RU2261104C2 (ru) 2005-09-27
CZ20021697A3 (cs) 2003-02-12
US20090298752A1 (en) 2009-12-03
NO330719B1 (no) 2011-06-20
PL355335A1 (en) 2004-04-19
HK1045648B (en) 2007-09-21
DE60035120D1 (de) 2007-07-19

Similar Documents

Publication Publication Date Title
SI1229922T1 (sl) Zdravljenje raka z aplidinom
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
AU5089799A (en) Drug complex for treatment of metastatic prostate cancer
WO2004045532A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
IL138330A0 (en) Polynucleotides, polypeptides and pharmaceutical compositions for treating lung cancer
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
YU69903A (sh) Postupak i dozni oblik za lečenje tumora primenom tegafura, uracila, folne kiseline, paklitaksela i karboplatina
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2002046416A3 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
MXPA02005045A (es) Preparaciones farmaceuticas que contiene agentes citostaticos y aceptores de electrones para el tratamiento de cancer.
BG108932A (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
ATE293991T1 (de) VERWENDUNG EINES MIT DEM PEPTID ßELAGIGILTVß ASSOZIIERTEN ENTEROBAKTERIEN-PROTEINS OMPA ZUR BEHANDLUNG VON MELANOMEN
HUP0300772A3 (en) Medicament for the immunotherapy of malignant tumours
WO1999056697A3 (en) Pharmaceutical composition
IL160382A0 (en) Use of 4-pyridylmethylphthalazines for cancer treatment
MY133682A (en) Substituted pyrroles
AU1991901A (en) Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
AU5706500A (en) Medicinal compositions for treating colorectal cancer
NO20051444L (no) Medikament inneholdende disorazoler og derivater av disse for behandling av benigne og maligne tumorsykdommer.
AU2001256440A1 (en) Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent